1. Home
  2. RVSN vs CALC Comparison

RVSN vs CALC Comparison

Compare RVSN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

HOLD

Current Price

$4.55

Market Cap

10.0M

Sector

N/A

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.76

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
CALC
Founded
2016
2011
Country
Israel
United States
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
9.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RVSN
CALC
Price
$4.55
$0.76
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
16.2K
1.0M
Earning Date
03-31-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
$860.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.61
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.46
52 Week High
$9.39
$7.20

Technical Indicators

Market Signals
Indicator
RVSN
CALC
Relative Strength Index (RSI) 45.25 44.77
Support Level $4.60 $0.52
Resistance Level $5.09 $0.93
Average True Range (ATR) 0.31 0.13
MACD 0.09 -0.02
Stochastic Oscillator 51.03 36.20

Price Performance

Historical Comparison
RVSN
CALC

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: